Rigel Pharmaceuticals, Inc. (RIGL) Income Statement
RIGL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRIGL revenue and net income
Where RIGL's revenue goes
2025Each bar shows an amount and its share of revenue. RIGL kept 124.7% of revenue as net income.
RIGL profit margins
RIGL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +64.1% | +34.8% | +22.1% | +26.1% |
| Gross profit | +71.0% | +32.3% | +20.6% | — |
| Operating income | +418.6% | — | — | — |
| Net income | +1,999.1% | — | — | — |
| EPS (diluted) | +590.4% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RIGL quarterly EPS vs estimates
Rigel Pharmaceuticals beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 3, 2026 (estimate $0.87).
RIGL income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M | $59.3M | $44.5M | $4.5M | $20.4M |
| Cost of revenue | $19.6M | $18.6M | $7.1M | $1.7M | $1.1M | $895,000 | $906,000 | $287,000 | $46.3M | $63.4M |
| Gross profit | $274.7M | $160.6M | $109.8M | $118.5M | $148.2M | $107.7M | $58.4M | $44.2M | −$41.8M | −$43.1M |
| Research & development | $33.3M | $23.4M | $24.5M | $60.3M | $65.2M | $60.1M | $52.9M | $46.9M | $46.3M | $63.4M |
| Sales, general & admin | $115.9M | $113.1M | $111.1M | $112.5M | $91.9M | $76.6M | $74.6M | $70.0M | $37.8M | $20.9M |
| Total operating expenses | $149.2M | $136.4M | $130.3M | $174.0M | $160.6M | $136.7M | $127.5M | $116.9M | $84.1M | $90.1M |
| Operating income | $125.5M | $24.2M | −$20.5M | −$55.5M | −$12.5M | −$29.0M | −$69.1M | −$72.7M | −$79.6M | −$69.7M |
| Interest income | $3.7M | $2.1M | $2.0M | $684,000 | $47,000 | $582,000 | $2.5M | $2.2M | $892,000 | $437,000 |
| Interest expense | $7.3M | $7.9M | $6.9M | $3.7M | $4.9M | $1.4M | $335,000 | $0 | $0 | $0 |
| Income before taxes | $121.8M | $18.4M | −$25.1M | −$58.6M | −$17.3M | −$29.7M | −$66.9M | −$70.5M | −$78.0M | −$69.2M |
| Income taxes | −$245.2M | $881,000 | $2.3M | $3.0M | $605,000 | $647,000 | −$348,000 | $2.2M | −$2.1M | $4.3M |
| Net income | $367.0M | $17.5M | −$25.1M | −$58.6M | −$17.9M | −$29.7M | −$66.5M | −$70.5M | −$78.0M | −$69.2M |
| EBITDA | $131.6M | $28.5M | −$17.0M | −$53.9M | −$11.3M | −$27.7M | −$65.9M | −$72.1M | −$77.5M | −$63.0M |
| EPS (diluted) | $6.49 | $0.94 | −$1.50 | −$3.49 | $0.07 | −$1.78 | −$4.00 | −$4.67 | −$4.59 | −$5.36 |
| Gross margin | 93.3% | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% | −931.9% | −211.3% |
| Operating margin | 42.6% | 13.5% | −17.5% | −46.2% | −8.4% | −26.7% | −116.5% | −163.3% | −1,775.6% | −342.2% |
| Net margin | 124.7% | 9.8% | −21.5% | −48.7% | −12.0% | −27.4% | −112.2% | −158.3% | −1,739.3% | −339.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.7M | $58.8M | $69.8M | $69.5M | $101.7M | $53.3M | $57.6M | $55.3M | $36.8M | $29.5M | $35.8M | $28.1M |
| Cost of revenue | $8.5M | $4.6M | $6.0M | $4.8M | $4.5M | $4.4M | $5.8M | $8.0M | $2.8M | $2.0M | $3.8M | $1.3M |
| Gross profit | $70.2M | $54.2M | $63.8M | $64.7M | $97.2M | $48.9M | $51.8M | $47.3M | $34.0M | $27.5M | $32.0M | $26.9M |
| Research & development | $14.0M | $11.7M | $10.7M | $7.4M | $6.8M | $8.4M | $5.6M | $6.2M | $5.5M | $6.0M | $3.2M | $6.5M |
| Sales, general & admin | $32.6M | $30.7M | $30.0M | $28.9M | $29.3M | $27.7M | $29.5M | $27.0M | $28.0M | $28.4M | $26.9M | $24.9M |
| Total operating expenses | $46.6M | $42.3M | $40.7M | $36.3M | $36.1M | $36.2M | $35.2M | $33.2M | $33.6M | $34.5M | $30.0M | $31.3M |
| Operating income | $23.6M | $11.9M | $23.2M | $28.4M | $61.1M | $12.8M | $16.7M | $14.1M | $447,000 | −$7.0M | $2.0M | −$4.5M |
| Interest income | $789,000 | $1.2M | $1.2M | $1.1M | $753,000 | $591,000 | $522,000 | $425,000 | $552,000 | $593,000 | $678,000 | $672,000 |
| Interest expense | $779,000 | $1.4M | $1.7M | $1.9M | $1.9M | $1.9M | $2.0M | $2.1M | $2.0M | $1.9M | $1.9M | $1.9M |
| Income before taxes | $23.6M | $11.7M | $22.7M | $27.6M | $60.0M | $11.5M | $15.2M | $12.4M | −$1.0M | −$8.2M | $737,000 | −$5.7M |
| Income taxes | $6.3M | $3.0M | −$245.4M | −$280,000 | $369,000 | $65,000 | $881,000 | — | — | $356,724 | $678,000 | $672,000 |
| Net income | $17.3M | $8.7M | $268.1M | $27.9M | $59.6M | $11.4M | $14.3M | $12.4M | −$1.0M | −$8.2M | $737,000 | −$5.7M |
| EBITDA | $25.2M | $13.7M | $25.0M | $30.1M | $62.5M | $14.0M | $17.8M | $15.1M | $1.6M | −$6.0M | $2.9M | −$3.5M |
| EPS (diluted) | $0.88 | $0.44 | $1.12 | $1.46 | $3.28 | $0.63 | $0.80 | $0.70 | −$0.06 | −$0.50 | $0.00 | −$0.30 |
| Gross margin | 89.2% | 92.2% | 91.5% | 93.2% | 95.6% | 91.7% | 89.9% | 85.5% | 92.4% | 93.1% | 89.4% | 95.5% |
| Operating margin | 30.0% | 20.2% | 33.2% | 40.9% | 60.1% | 23.9% | 28.9% | 25.4% | 1.2% | −23.6% | 5.5% | −15.9% |
| Net margin | 22.0% | 14.7% | 384.0% | 40.2% | 58.6% | 21.5% | 24.9% | 22.5% | −2.8% | −27.9% | 2.1% | −20.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RIGL's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RIGL financial results
In fiscal year 2025 (ended December 31, 2025), Rigel Pharmaceuticals reported revenue of $294.3 million, up 64.1% from the year before. It had net income of $367.0 million (up 1,999.1%), a net profit margin of 124.7%. Diluted earnings per share came to $6.49. Over five years revenue grew at an average rate of 22.1% a year.
See the RIGL stock overview for the latest quote and news, or the RIGL chart for price history and technical indicators.
RIGL income statement FAQ
What is Rigel Pharmaceuticals's annual revenue?
Rigel Pharmaceuticals reported total revenue of $294.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 64.1% from $179.3 million the previous year.
Is Rigel Pharmaceuticals profitable?
Yes. Rigel Pharmaceuticals reported net income of $367.0 million in fiscal 2025, a net profit margin of 124.7%; its operating margin was 42.6%.
What is Rigel Pharmaceuticals's gross margin?
Rigel Pharmaceuticals's gross margin was 93.3% in fiscal 2025: for every $100 of revenue, Rigel Pharmaceuticals kept $93 after the direct cost of its products and services.
How much does Rigel Pharmaceuticals spend on research and development?
Rigel Pharmaceuticals spent $33.3 million on research and development in fiscal 2025, 11.3% of revenue.
How fast is Rigel Pharmaceuticals growing?
Revenue grew 22.1% a year on average over the last five fiscal years, from $108.6 million to $294.3 million.
What are Rigel Pharmaceuticals's earnings per share?
Rigel Pharmaceuticals earned $6.49 per diluted share in fiscal 2025, compared with $0.94 a year earlier.
When will Rigel Pharmaceuticals report its next earnings?
Rigel Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does Rigel Pharmaceuticals's fiscal year end?
Rigel Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.